VBData· 动脉网-最新·· 3 hours agoPickScore67
Ribotest Biotech Launches Hong Kong IPO Offering 27.4874 Million H Shares
In brief
Ribotest Biotech (06938.HK) launched its Hong Kong Stock Exchange offering on December 31, 2025, planning a global sale of 27.4874 million H shares at HK$57.97 per share. Listing is expected on January 9, 2026, with CICC and Citi acting as joint sponsors.
Why it matters
Source provides pipeline stage of FXI siRNA RBD4059, the $2 billion Boehringer Ingelheim deal and IPO pricing as benchmarks for oligonucleotide financing and valuation.
Source: VBData